Payment overview · 2025
General Payments
$59.00
3 reported records · 2 companies
Healthcare provider profile · identity verified
Matthew Solverson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DARLINGTON, WI · NPI 1154300507
Verified facts
What the public records show
CMS Open Payments records show Matthew Solverson, M.D. received $59.00 in general payments during 2025 across 3 reported records.
SUN PHARMACEUTICAL INDUSTRIES INC. accounted for 65.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $38.88 | 65.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.12 | 34.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $59.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Odomzo Normalized: odomzo |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $38.88 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 156 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
156 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 482 | 126 |
| Lisinopril | Lisinopril | 335 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 65 |
| Omeprazole | Omeprazole | 240 | 64 |
| Furosemide | Furosemide | 210 | 61 |
| Potassium Chloride | Potassium Chloride | 197 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 168 | 37 |
| Losartan Potassium | Losartan Potassium | 164 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 158 | 41 |
| Eliquis | Apixaban | 156 | 31 |
| Jardiance | Empagliflozin | 155 | 29 |
| Gabapentin | Gabapentin | 154 | 39 |
| Metformin Hcl | Metformin Hcl | 151 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 38 |
| Allopurinol | Allopurinol | 118 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 29 |
| Simvastatin | Simvastatin | 94 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 25 |
| Prednisone | Prednisone | 90 | 40 |
| Spironolactone | Spironolactone | 89 | 25 |
| Ezetimibe | Ezetimibe | 85 | 25 |
| Mirtazapine | Mirtazapine | 80 | 21 |
| Ozempic | Semaglutide | 80 | 15 |
| Tramadol Hcl | Tramadol Hcl | 74 | 14 |
| Montelukast Sodium | Montelukast Sodium | 73 | 14 |
| Lorazepam | Lorazepam | 69 | 15 |
| Famotidine | Famotidine | 68 | 24 |
| Trazodone Hcl | Trazodone Hcl | 65 | 22 |
| Alprazolam | Alprazolam | 62 | suppressed |
| Carvedilol | Carvedilol | 61 | 18 |
| Donepezil Hcl | Donepezil Hcl | 58 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 16 |
| Xarelto | Rivaroxaban | 54 | 12 |
| Azithromycin | Azithromycin | 51 | 43 |
| Finasteride | Finasteride | 51 | 13 |
| Metformin Hcl Er | Metformin Hcl | 44 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 16 |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Atenolol | Atenolol | 40 | 11 |
| Farxiga | Dapagliflozin Propanediol | 40 | 12 |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Nystatin | Nystatin | 27 | 17 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 13 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Colchicine | Colchicine | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lorazepam Intensol | Lorazepam | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $59.00 · 3 records | SUN PHARMACEUTICAL INDUSTRIES INC. | ELIQUIS, NURTEC ODT, Odomzo | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error